Abstract: SA-PO0860
Characteristics of Patients with IgAN Treated with Mycophenolate Mofetil in the Real World
Session Information
- Glomerular Management: Real-World Lessons and Emerging Therapies
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Tatis, Efrain, Vall d' Hebron Hospital, Barcelona, Spain
- Yandian, Federico, Clinical Hospital, Montevideo, Uruguay
- Nunez-Delgado, Sara, Vall d' Hebron Hospital, Barcelona, Spain
- Bermejo Garcia, Sheila, Vall d' Hebron Hospital, Barcelona, Spain
- Ramos, Natalia, Vall d' Hebron Hospital, Barcelona, Spain
- Gabaldon, Alejandra, Vall d' Hebron Hospital, Barcelona, Spain
- Alvarez, Tiffany M., Vall d' Hebron Hospital, Barcelona, Spain
- Agraz Pamplona, Irene, Vall d' Hebron Hospital, Barcelona, Spain
- León Román, Juan Carlos, Vall d' Hebron Hospital, Barcelona, Spain
- López-Martínez, Marina, Vall d' Hebron Hospital, Barcelona, Spain
- Soler Romeo, Maria Jose, Vall d' Hebron Hospital, Barcelona, Spain
Background
IgA nephropathy (IgAN) is the most common primary glomerulonephritis, with up to 40% of patients developing kidney failure within 10 years. This study evaluates the efficacy of mycophenolate mofetil or mycophenolic acid (MMF) in IgAN in non-Chinese populations.
Methods
Multicenter study (2 centers) involving patients with biopsy-confirmed IgAN and ≥6 months follow-up. Patients were divided into three groups based on the treatment received within the first 6 months post-biopsy: (1)MMF, (2)Oral steroids, and (3)Supportive care. Data were collected at baseline and during follow-up 3, 6, and 12months, and annually up to 5 years, assessing changes in estimated glomerular filtration rate(eGFR), creatinine, hematuria, proteinuria, and blood pressure. Outcomes included eGFR<15ml/min, dialysis, transplantation, death, or initiation of another immunosuppressant
Results
94 patients were included: 27 MMF, 24 steroid, and 43 supportive care group. The MMF and steroid groups had more severe disease at baseline. Worse baseline renal function (p=0.01), hematuria (p=0.008), inflammatory bowel disease (p=0.001), and C score (p=0.001) were predictors of poorer prognosis. The MMF group showed a greater reduction in hematuria (99.7%vs51.5%, p=0.02) and proteinuria (81.84%vs68%, p=0.034) compared to supportive care. However, the supportive care group had a lower event rate (p=0.004), likely due to a better’s baseline characteristics.
Conclusion
Patients treated with MMF, despite having more severe disease, achieved greater reductions in proteinuria and hematuria but experienced more events. Additional studies are needed to confirm the utility of MMF in non-Asian populations.